Market data
Medical Conditions Disorders
Explore verified medical conditions disorders statistics and market research reports with sourced data and trend analysis.
Latest update:
Elif Demirci
Prostate Cancer Treatment Statistics
With 2024 US prostate cancer deaths estimated at 35,250 and real world care patterns still varying, this statistics page connects outcomes and side effects across modern standards, from PSMA PET staging and risk adapted diagnosis to hormone treatment and metastatic trial benchmarks. You will see how newer intensification strategies translate into measurable survival gains and how toxicity profiles shift, including grade 3 or higher event rates ranging from about 37% to 51% depending on therapy and setting.
Emphysema Statistics
Even with emphysema’s CT and DLCO measures that can quantify severity, health systems miss a large share of COPD, and indirect costs from COPD are estimated at $2.2 billion every year in the US. From smoking cessation and Alpha 1 antitrypsin deficiency to oxygen, rehabilitation, and vaccination benefits, the page connects what drives risk to what actually changes outcomes, including a 14% reduction in annual exacerbations in the UPLIFT trial.
Yellow Fever Statistics
See how yellow fever can look both predictable and surprisingly fragile across Americas and Africa, with vector cycles, case definitions, and vaccine durability all mapped to measurable outcomes including an 83.0% pooled effectiveness against confirmed yellow fever and 10 year persistence of protective neutralizing antibodies. The page ties mosquito biology and phylogenetic timing to real-world burden and outbreak strategy, including how fractional dosing stretches supply and how low herd immunity can help explain why outbreaks still surge.
Ewing Sarcoma Prognosis Statistics
See how Ewing sarcoma prognosis measures up in the most recent snapshot, including current 5 year survival rates and who is most affected by age and disease stage. You will also see the tension between treatment timing and outcome, with recurrence and metastasis risk statistics that can change what patients and families plan for next.
Child Cancer Statistics
Even with progress, the numbers for childhood cancer still carry urgency. See how the most recent survival and diagnosis figures, including the 2025 estimates for new cases, shape what families and advocates need to push for next.
Male Infertility Statistics
Male infertility isn’t a rare, vague problem and the 2025 figures put numbers to what many couples quietly experience, with several key measures tracking a clear shift in who is most affected. Get the statistics that help separate myths from patterns and show where prevention, diagnosis, and treatment attention is most likely to pay off in real life.
Pancreatic Cancer Prognosis Statistics
Pancreatic cancer outcomes hinge on details, from an age-adjusted US mortality rate of about 10.9 per 100,000 to median survival swinging from roughly 20 to 40 months after R0 resection versus 3 to 6 months with metastatic best supportive care. This Prognosis statistics page connects those gaps to evidence and biology, including resection margin effects, trial benchmarks like 54.4 months with gemcitabine based chemo in PRODIGE 4 ACCORD 11, and biomarker frequencies such as germline mutations near 10% and MSI H around 1 to 2%.
Childhood Cancer Awareness Statistics
Some children survive cancer but still face severe or life threatening after effects, and survival drops from about 70% in high income countries to around 25% in low and middle income settings. Read why public awareness gaps and diagnostic delays matter, from 38% of caregivers delaying care because they did not recognize seriousness to a 2025 comparison that shows a 63 per million person year global mortality rate for ages 0 to 19 alongside the research and referral systems working to change the outcome.
Latest Covid Statistics
Latest Covid is tracking how protection and risk have shifted, from a 47% lower hospitalization risk after the Omicron era bivalent booster to Omicron vaccine effectiveness against symptomatic infection dropping to near zero 20+ weeks later. It also pulls the most up to date operational signals, including 34.7% of US nursing homes reporting a case as of the week ending 2024-01-31, alongside real-world long COVID impacts such as 13.0% of adults affected after infection.
Skin Cancer Statistics
With 97,610 projected new melanoma cases in the US in 2024, the stakes are high even as evidence repeatedly points to prevention, from sunscreen cutting squamous cell carcinoma and melanoma risk by about 40% to tanning beds raising skin cancer danger. This page also connects survival and trend data with practical care tools, including FDA cleared AI diagnostics and teledermatology that shortens time to diagnosis.
Sickle Cell Race Statistics
See how Sickle Cell Race performance and enrollment move in 2026, where the pattern shifts fast from early effort to measurable outcomes. You will also find the hard contrasts between race participation and results that explain why progress can look uneven until you track the right metrics.
Vaginismus Statistics
Vaginismus is not rare or purely psychological, and the newest figures make that harder to ignore than ever. Read these up to date statistics to see how frequently people report pain, avoidance, and delayed care so you can understand what is common and what treatment decisions often miss.
Congenital Heart Disease Statistics
Congenital heart disease remains the leading birth defect, affecting 1 in every 110 babies each year, yet the early survival picture is uneven and often missed until complications arise. Get the latest, practical statistics on incidence, outcomes, and risk patterns that can change how clinicians, families, and systems prepare.
Uterine Cancer Statistics
See how uterine corpus cancer can be both surprisingly survivable and still tightly linked to preventable risk, with 84% 5-year relative survival for endometrial cancer overall alongside notes that tamoxifen use raises risk and many cases are found after abnormal uterine bleeding. You will also find current, practice relevant outcomes and costs, including 74.4% 2-year progression free survival with pembrolizumab plus chemotherapy versus 38.1% with chemotherapy alone, and Medicare spending of $1.7 billion on uterine cancer services in 2021.
Pulmonary Hypertension Statistics
How do you reconcile 83% 2 year survival on oral therapy for PAH patients who stayed the course with a steep risk gap where 15% are already high risk at diagnosis and 6 minute walk distance drops as PAH risk climbs. Get the page wide view from US prevalence at 15.1 cases per million and rising PH hospitalizations from 2005 to 2014 to which drugs actually move survival in severe PAH, plus the DALY weight PH places on global disability.
Chd Statistics
CHD’s latest CHD statistics show how quickly the picture is shifting, with the 2026 figures highlighting changes you would miss if you only looked a year or two back. The page puts the biggest numbers side by side so you can see exactly what’s moving and what is staying stubbornly the same.
Sensory Processing Disorder Statistics
Nearly 1 in 6 children has a sensory processing pattern that can make everyday life feel unpredictably loud, messy, or hard to navigate, even when they are trying their best. The page turns that pressure into clear, 2026-relevant numbers that show exactly where the strain hits most and why early support can make the difference.
Nsclc Statistics
Nsclc survival and treatment outcomes in 2025 are moving in a direction patients and clinicians can feel, with results that look meaningfully different depending on stage. This page gathers the most current statistics so you can see where progress is real and where the gaps still remain.
Rickets Statistics
See how Rickets stats shifted recently, with 2026 figures showing the sharpest change yet in what people actually do and how often they return. The contrast between the latest totals and the earlier pattern is the whole point, and it makes the next decision much clearer.
Erectile Dysfunction Statistics
Erectile dysfunction is more common than many people realize, with 1 in 2 men affected to some degree by age 40 to 70. The most revealing part is how quickly risk rises with age and cardiovascular health, so the earlier you understand the pattern, the better you can spot what is changing before it becomes harder to treat.